Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Picard Medical, Inc. ( (PMI) ) has issued an update.
On March 2, 2026, Picard Medical announced that Vice President of Clinical Affairs Dr. Andre Simon would deliver three presentations at the Technology and Heart Failure Therapeutics 2026 conference in Boston, running from March 2 to March 4. His talks cover new data on the current SynCardia Total Artificial Heart and early in vitro and in vivo results for the fully implantable next-generation Emperor system, as well as broader themes on the future of total artificial heart therapy.
The scientific and clinical outcomes data to be presented underscore that SynCardia Total Artificial Heart benefits extend beyond survival to include organ recovery, functional improvement, and preservation of transplant eligibility, particularly when implanted earlier in the disease course. By showcasing preclinical progress on the Emperor system and emphasizing quality of life and long-term independence, Picard seeks to reinforce its leadership in mechanical circulatory support and signal continued innovation that could influence treatment strategies for advanced heart failure and stakeholder expectations around durable artificial heart solutions.
The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down mainly by very weak fundamentals (large ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates and financing improve near-term runway and visibility, but do not yet offset the current profitability and cash-flow risks.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc., listed on NYSE American, is the parent of SynCardia Systems, a Tucson-based leader in total artificial heart technology for end-stage heart failure patients. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, the first artificial heart approved by both the U.S. FDA and Health Canada and currently the only commercially available artificial heart in the United States and Canada.
With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart globally. The implantable system assumes the circulatory functions of a failing or failed human heart, positioning Picard Medical and SynCardia at the forefront of advanced mechanical circulatory support solutions.
Average Trading Volume: 1,609,876
Technical Sentiment Signal: Strong Sell
See more data about PMI stock on TipRanks’ Stock Analysis page.